Medication Related Osteonecrosis of the Jaw (MRONJ). Review and recent advances

[1] Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al (2014). American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg, 72:1938–1956. Doi: 10.1016/j.joms.2014.04.031. RuggieroSL DodsonTB FantasiaJ GooddayR AghalooT MehrotraB 2014 American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update J Oral Maxillofac Surg 72 1938 1956 10.1016/j.joms.2014.04.031 Open DOISearch in Google Scholar

[2] Owosho AA, Blanchard A, Levi L, Kadempour A, Rosenberg H, Yom SK, et al (2016). Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. J Craniomaxillofac Surg 44:265–70, doi: 10.1016/j.jcms.2015.12.005. OwoshoAA BlanchardA LeviL KadempourA RosenbergH YomSK 2016 Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients J Craniomaxillofac Surg 44 265 70 10.1016/j.jcms.2015.12.005 Open DOISearch in Google Scholar

[3] Schiodt M, Vadhan-Raj S, Chambers MS, Nicolatou-Galitis O, Politis C, Coropciuc R, et al (2018). A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer 26: 1905–1915, Doi: 10.1007/s00520-017-4003-2. SchiodtM Vadhan-RajS ChambersMS Nicolatou-GalitisO PolitisC CoropciucR 2018 A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer Support Care Cancer 26 1905 1915 10.1007/s00520-017-4003-2 Open DOISearch in Google Scholar

[4] Migliorati CA, Brennan MT, Peterson DE (2019). Medication-Related Osteonecrosis of the Jaws.J Natl Cancer Inst Monogr 53, doi: 10.1093/jncimonographs/lgz009. MiglioratiCA BrennanMT PetersonDE 2019 Medication-Related Osteonecrosis of the Jaws J Natl Cancer Inst Monogr 53 10.1093/jncimonographs/lgz009 Open DOISearch in Google Scholar

[5] Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 61:115–117. MarxRE 2003 Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic J Oral Maxillofac Surg 61 115 117 Search in Google Scholar

[6] Migliorati CA (2003). Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254. MiglioratiCA 2003 Bisphosphonates and oral cavity avascular bone necrosis Clin Oncol 21 4253 4254 Search in Google Scholar

[7] Wang J, Goodger NM, Pogrel MA (2003). Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–7. WangJ GoodgerNM PogrelMA 2003 Osteonecrosis of the jaws associated with cancer chemotherapy J Oral Maxillofac Surg 61 1104 7 Search in Google Scholar

[8] Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al (2010). Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:191–188. GuarneriV MilesD RobertN DiérasV GlaspyJ SmithI 2010 Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer Breast Cancer Res Treat 122 191 188 Search in Google Scholar

[9] Fusco V, Santini D, Armento G, Tonini G, Campisi G (2016). Osteonecrosis of the jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opinion on Drug Safety 15:7, 925–935. FuscoV SantiniD ArmentoG ToniniG CampisiG 2016 Osteonecrosis of the jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology Expert Opinion on Drug Safety 15 7 925 935 Search in Google Scholar

[10] Pimolbutr K, Porter S, Fedele S (2018). Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naïve patient: a comprehensive review of the literature. Bio Med Res Int 14. Doi: 10.1155/2018/8071579. PimolbutrK PorterS FedeleS 2018 Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naïve patient: a comprehensive review of the literature Bio Med Res Int 14 10.1155/2018/8071579 Open DOISearch in Google Scholar

[11] Mahedi Mohamed HA, Nor Nielsen CE, Schiodt M (2018). Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of seven cases from the Copenhagen ONJ cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 125:157–163, https://doi.org/10.1016/j.oooo.2017.10.010. Mahedi MohamedHA Nor NielsenCE SchiodtM 2018 Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of seven cases from the Copenhagen ONJ cohort Oral Surg Oral Med Oral Pathol Oral Radiol 125 157 163 https://doi.org/10.1016/j.oooo.2017.10.010. Search in Google Scholar

[12] Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D et al (2019a). Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review. Support Care Cancer 27:383–394, Doi: 10.1007/s00520-018-4501-x. Nicolatou-GalitisO KouriM PapadopoulouE VardasE GalitiD 2019a Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review Support Care Cancer 27 383 394 10.1007/s00520-018-4501-x Open DOISearch in Google Scholar

[13] Christodoulou C, Pervena A, Klouvas G, et al (2009). Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209–211. ChristodoulouC PervenaA KlouvasG 2009 Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone Oncology 76 209 211 Search in Google Scholar

[14] Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al (2012). Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 6:1665–71. BeuselinckB WolterP KaradimouA ElaidiR DumezH RogiersA 2012 Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases Br J Cancer 6 1665 71 Search in Google Scholar

[15] Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F (2013). Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 71:1532–40. Smidt-HansenT FolkmarTB FodeK AgerbaekM DonskovF 2013 Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma J Oral Maxillofac Surg 71 1532 40 Search in Google Scholar

[16] Van Cann T, Loyson T, Verbiest A, Clement PM, Becher O, Willems L, et al (2018). Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26: 869–878. DOI 10.1007/s00520-017-3903-5. Van CannT LoysonT VerbiestA ClementPM BecherO WillemsL 2018 Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors Support Care Cancer 26 869 878 10.1007/s00520-017-3903-5 Open DOISearch in Google Scholar

[17] Yarom N, Lazarovizi TS, Whitefield S, Weissman et al (2018). Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab. Oral Surg Oral Med Oral Pathol Oral Radiol 125;27–30. YaromN LazaroviziTS WhitefieldS Weissman 2018 Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab Oral Surg Oral Med Oral Pathol Oral Radiol 125 27 30 Search in Google Scholar

[18] Srivastava A, Nogueras Gonzalez GM, Geng Y, Won A M, Cabanillas ME, Naing A, et al (2021). Prevalence of medication related osteonecrosis of the jaw in patients with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 29:2305–2317. SrivastavaA Nogueras GonzalezGM GengY WonA M CabanillasME NaingA 2021 Prevalence of medication related osteonecrosis of the jaw in patients with sequential antiresorptive drugs: systematic review and meta-analysis Support Care Cancer 29 2305 2317 Search in Google Scholar

[19] Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, et al (2019). Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges. Oral Dis 25:1815–1821, doi: 10.1111/odi.13160. SchiodtM OttoS FedeleS BedogniA Nicolatou-GalitisO GuggenbergerR 2019 Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges Oral Dis 25 1815 1821 10.1111/odi.13160 Open DOISearch in Google Scholar

[20] Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vesconi P, Mafredi M, et al (2010). Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series. Am J Med 123:1060–1064. FedeleS PorterSR D'AiutoF AljohaniS VesconiP MafrediM 2010 Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series Am J Med 123 1060 1064 Search in Google Scholar

[21] Patel S, Choyee S, Uyanne J, Nguyen AL, Lee P, Sedghizadehet PP, et al (2012). Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis 18: 625–632. PatelS ChoyeeS UyanneJ NguyenAL LeeP SedghizadehetPP 2012 Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines Oral Dis 18 625 632 Search in Google Scholar

[22] Schiodt M, Reibel J, Oturai P, Kofod T (2014). Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117:204–213, Doi: 10.1016/j.oooo.2013.10.010. SchiodtM ReibelJ OturaiP KofodT 2014 Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system Oral Surg Oral Med Oral Pathol Oral Radiol 117 204 213 10.1016/j.oooo.2013.10.010 Open DOISearch in Google Scholar

[23] Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, et al (2015). Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg, 53:13–17. Doi: 10.1016/j.bjoms.2014.09.001. FedeleS BedogniG ScolettaM FaviaG ColellaG AgrilloA 2015 Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed Br J Oral Maxillofac Surg 53 13 17 10.1016/j.bjoms.2014.09.001 Open DOISearch in Google Scholar

[24] Yarom N, Shapiro CL, Peterson DE, Van Poznac CH, Bohlke K, Ruggiero SL, et al (2019). Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 37:2270–2290, doi.org/10.1200/JCO.19.01186. YaromN ShapiroCL PetersonDE Van PoznacCH BohlkeK RuggieroSL 2019 Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline J Clin Oncol 37 2270 2290 doi.org/10.1200/JCO.19.01186. Search in Google Scholar

[25] Saad F, Brown JE, Van Poznak C, et al (2012). Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol: official journal of the European Society for Medical Oncology / ESMO 23: 1341–1347. SaadF BrownJE Van PoznakC 2012 Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Ann Oncol: official journal of the European Society for Medical Oncology / ESMO 23 1341 1347 Search in Google Scholar

[26] Rugani P, Walter C, Kirnbauer B, Achan S, Begus-Nahrman Y, Jakse N (2016). Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dentistry Journal 32; doi: 10.3390/dj4040032. RuganiP WalterC KirnbauerB AchanS Begus-NahrmanY JakseN 2016 Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma Dentistry Journal 32 10.3390/dj4040032 Open DOISearch in Google Scholar

[27] Fung PPL, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G et al (2017). Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicenter retrospective cohort study. Oral Dis, 23:477–483, Doi: 10.1111/odi.12632. FungPPL BedogniG BedogniA PetrieA PorterS CampisiG 2017 Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicenter retrospective cohort study Oral Dis 23 477 483 10.1111/odi.12632 Open DOISearch in Google Scholar

[28] Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M. (2018). Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment Reviews, 69, 177–187, Doi: 10.1016/j.ctrv.2018.06.007. OttoS PautkeC Van den WyngaertT NiepelD SchiodtM 2018 Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases Cancer Treatment Reviews 69 177 187 10.1016/j.ctrv.2018.06.007 Open DOISearch in Google Scholar

[29] Hallmer F, Bjarnadottir O, Gotric B, Malmstrom P, Anderson G (2020). Incidence and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol 130:252–257. HallmerF BjarnadottirO GotricB MalmstromP AndersonG 2020 Incidence and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study Oral Surg Oral Med Oral Pathol Oral Radiol 130 252 257 Search in Google Scholar

[30] Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, et al (2022). Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study. Supportive Care Cancer 30:4505–4514. HataH ImamachiK UedaM MatsuzakaM HiragaH OsanaiT 2022 Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study Supportive Care Cancer 30 4505 4514 Search in Google Scholar

[31] Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, et al (2022). Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer 30:2341–2348. IkesueH DoiK MorimotoM HirabatakeM MuroiN YamamotoS 2022 Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis Support Care Cancer 30 2341 2348 Search in Google Scholar

[32] Fusco V, Campisi G, Bedogni A (2022). One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). Support Care Cancer, doi.org/10.1007/s00520-022-06982-y. FuscoV CampisiG BedogniA 2022 One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ) Support Care Cancer doi.org/10.1007/s00520-022-06982-y. Search in Google Scholar

[33] Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, et al (2018). Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 125:547–551. HiguchiT SogaY MuroM KajizonoM KitamuraY SendoT 2018 Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw Oral Surg Oral Med Oral Pathol Oral Radiol 125 547 551 Search in Google Scholar

[34] Yazdi PM, Schiodt M. (2015). Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 119:416–422, doi: 10.1016/j.oooo.2014.12.024. YazdiPM SchiodtM 2015 Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort Oral Surg Oral Med Oral Pathol Oral Radiol 119 416 422 10.1016/j.oooo.2014.12.024 Open DOISearch in Google Scholar

[35] Matsuo A, Hamada H, Kaise H, Chikazu D, Yamada K, Kohno N (2014). Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer. Acta Odontol Scand 72: 656–663. MatsuoA HamadaH KaiseH ChikazuD YamadaK KohnoN 2014 Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer Acta Odontol Scand 72 656 663 Search in Google Scholar

[36] Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, et al. (2015). Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg 43: 847–854, Doi: 10.1016/j.jcms.2015.03.039. OttoS TroltzschM JambrovicV PanyaS ProbstF RistowO 2015 Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg 43 847 854 10.1016/j.jcms.2015.03.039 Open DOISearch in Google Scholar

[37] Kamimura M, Taguch A, Komatsu M, Koiwai H, Ashizawa R, Ichinose A, et al (2018). Long waiting before tooth extraction may increase delayed wound healing in elderly Japanese. Osteoporosis Intern doi: 10.1007/s00198-018-4775-3. KamimuraM TaguchA KomatsuM KoiwaiH AshizawaR IchinoseA 2018 Long waiting before tooth extraction may increase delayed wound healing in elderly Japanese Osteoporosis Intern 10.1007/s00198-018-4775-3 Open DOISearch in Google Scholar

[38] Soutome S, Hayashida S, Funahara M, Sakamoto Y, Kojima Y, Yamamoto S, et al (2018). Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? PLOS One, doi: .org/10.1371/journal.pone.0201343. SoutomeS HayashidaS FunaharaM SakamotoY KojimaY YamamotoS 2018 Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? PLOS One doi: .org/10.1371/journal.pone.0201343. Search in Google Scholar

[39] Nicolatou-Galitis O, Papadopoulou E, Vardas E, Kouri M, Galiti D, Galitis E, et al (2020). Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis. 2020 Jul;26(5):955–966. doi: 10.1111/odi.13294. Epub 2020 Mar 3. PMID: 32011077. Nicolatou-GalitisO PapadopoulouE VardasE KouriM GalitiD GalitisE 2020 Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents Oral Dis. 2020 Jul 26 5 955 966 10.1111/odi.13294 Epub 2020 Mar 3. PMID: 32011077. Open DOISearch in Google Scholar

[40] Ristow O, Ruckschlob T, Moratin J, Muller M, et al (2021a). Wound closure and alveoloplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot study. Oral Dis 27:532–546. RistowO RuckschlobT MoratinJ MullerM 2021a Wound closure and alveoloplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot study Oral Dis 27 532 546 Search in Google Scholar

[41] Nicolatou-Galitis O, Schiodt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al (2019b). Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis and management. Oral Surg Oral Med Oral Pathol Oral Radiol 127:117–135. Doi: 10.1016/j.oooo.2018.09.008 Nicolatou-GalitisO SchiodtM MendesRA RipamontiC HopeS Drudge-CoatesL 2019b Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis and management Oral Surg Oral Med Oral Pathol Oral Radiol 127 117 135 10.1016/j.oooo.2018.09.008 Open DOISearch in Google Scholar

[42] Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al (2017). Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017 Jan;35(1):6–19. doi: 10.1007/s00774-016-0810-7. YonedaT HaginoH SugimotoT OhtaH TakahashiS SoenS 2017 Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw J Bone Miner Metab 2017 Jan 35 1 6 19 10.1007/s00774-016-0810-7 Open DOISearch in Google Scholar

[43] Dutra KL, Haas LF, Zimmermann GS, et al (2019). Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis. Dentomaxillofac Radiol 48 doi: 10.1259/dmfr.20180112. DutraKL HaasLF ZimmermannGS 2019 Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis Dentomaxillofac Radiol 48 10.1259/dmfr.20180112 Open DOISearch in Google Scholar

[44] Moreno-Rabie C, Gaeta-Araujo H, Oliveira-Santos C, Politis C, et al (2020). Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review. Clin Oral Investig 24:2973–2989. Moreno-RabieC Gaeta-AraujoH Oliveira-SantosC PolitisC 2020 Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review Clin Oral Investig 24 2973 2989 Search in Google Scholar

[45] Wongratwanich P, Shimabukuro K, Konishi M, Nagasaki T, Ohtsuka M, Suei Y, Nakamoto T, Verdonschot RG, Kanesaki T, Sutthiprapaporn P, Kakimoto N (2021). Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review. Dentomaxillofac Radiol. 1;50(6):20200417. doi: 10.1259/dmfr.20200417. WongratwanichP ShimabukuroK KonishiM NagasakiT OhtsukaM SueiY NakamotoT VerdonschotRG KanesakiT SutthiprapapornP KakimotoN 2021 Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review Dentomaxillofac Radiol 1; 50 6 20200417. 10.1259/dmfr.20200417 Open DOISearch in Google Scholar

[46] Tsiklakis K. and Karayanni A. (2018). Oral Diagnosis and Radiology. Athens, Greece, Litsas Medical editions. TsiklakisK. KarayanniA. 2018 Oral Diagnosis and Radiology Athens, Greece Litsas Medical editions Search in Google Scholar

[47] Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, et al (2014). Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg 52: 603–608, Doi: 10.1016/j.bjoms.2014.04.009. BedogniA FedeleS BedogniG ScolettaM FaviaG ColellaG 2014 Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease Br J Oral Maxillofac Surg 52 603 608 10.1016/j.bjoms.2014.04.009 Open DOISearch in Google Scholar

[48] Ristow O, Schung G, Smielowksi M, Moratin J, Pilz M, Engel M, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone changes before tooth extractions in patients with antiresorptive intake. Oral Dis. 2021 Oct 12. doi: 10.1111/odi.14048. RistowO SchungG SmielowksiM MoratinJ PilzM EngelM 2021b Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone changes before tooth extractions in patients with antiresorptive intake Oral Dis. 2021 Oct 12 10.1111/odi.14048 Open DOISearch in Google Scholar

[49] Cardoso CL, Barros CA, Curra C, Fernandes LM, Franzolin SO, Júnior JS, et al (2017). Radiographic Findings in Patients with Medication-Related Osteonecrosis of the Jaw. Int J Dent 2017:3190301. CardosoCL BarrosCA CurraC FernandesLM FranzolinSO JúniorJS 2017 Radiographic Findings in Patients with Medication-Related Osteonecrosis of the Jaw Int J Dent 2017 3190301. Search in Google Scholar

[50] Lentzen MP, Buller J, Riekert M, Grandoch A, Kreppel M, Zöller JE, Zirk M (2021). Bisphosphonate application and volumetric effects on MRONJ lesions. J Craniomaxillofac Surg. 49(6):501–507. doi: 10.1016/j.jcms.2021.01.014. LentzenMP BullerJ RiekertM GrandochA KreppelM ZöllerJE ZirkM 2021 Bisphosphonate application and volumetric effects on MRONJ lesions J Craniomaxillofac Surg 49 6 501 507 10.1016/j.jcms.2021.01.014 Open DOISearch in Google Scholar

[51] Soundia A, Hadaya D, Mallya SM, Aghaloo TL, Tetradis S (2018). Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 126:537–544, doi: 10.1016/j.oooo.2018.08.005. SoundiaA HadayaD MallyaSM AghalooTL TetradisS 2018 Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws Oral Surg Oral Med Oral Pathol Oral Radiol 126 537 544 10.1016/j.oooo.2018.08.005 Open DOISearch in Google Scholar

[52] Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, et al (2021). Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer 29:2509–2517. KizubDA MiaoJ SchubertMM PatersonAHG ClemonsM DeesEC 2021 Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307) Support Care Cancer 29 2509 2517 Search in Google Scholar

[53] Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–129. DimopoulosMA KastritisE BamiaC MelakopoulosI GikaD RoussouM 2009 Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann Oncol 20 117 129 Search in Google Scholar

[54] Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al (2009). Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145, doi: 10.1093/annonc/mdn526. RipamontiCI ManiezzoM CampaT FagnoniE BrunelliC SaibeneG 2009 Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan Ann Oncol 20 137 145 10.1093/annonc/mdn526 Open DOISearch in Google Scholar

[55] Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al (2011). American Society of Clinical Oncology Executive summary of the clinical Practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221–1227, doi: 10.1200/jco.2010.32.5209. Van PoznakCH TeminS YeeGC JanjanNA BarlowWE BiermannJS 2011 American Society of Clinical Oncology Executive summary of the clinical Practice guideline update on the role of bone-modifying agents in metastatic breast cancer J Clin Oncol 29 1221 1227 10.1200/jco.2010.32.5209 Open DOISearch in Google Scholar

[56] Villafuerte KRV, Dantas Ft, Taba M Jr, Messora M, Candido dos Reis F, Carrara HHA et al (2021). Effects of non-surgical periodontal therapy on the cytokine profile in gingival crevicular fluid of breast cancer patients with periodontitis undergoing chemotherapy. Support Care Cancer 29:7505–7513. VillafuerteKRV DantasFt TabaMJr MessoraM Candido dos ReisF CarraraHHA 2021 Effects of non-surgical periodontal therapy on the cytokine profile in gingival crevicular fluid of breast cancer patients with periodontitis undergoing chemotherapy Support Care Cancer 29 7505 7513 Search in Google Scholar

[57] Coropciuc RG, Grisar K, Aerden T, Schol M, Schoenaers J, Politis C (2017). Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg 55:787–792. CoropciucRG GrisarK AerdenT ScholM SchoenaersJ PolitisC 2017 Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2 Br J Oral Maxillofac Surg 55 787 792 Search in Google Scholar

[58] Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, et al (2017). Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis. J Bone Miner Res 32:2022–2029, doi: 10.1002/jbmr.3191. HayashidaS SoutomeS YanamotoS FujitaS HasegawaT KomoriT KojimaY MiyamotoH 2017 Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis J Bone Miner Res 32 2022 2029 10.1002/jbmr.3191 Open DOISearch in Google Scholar

[59] Ramaglia L, Guida A, Lorio-Siciliano V, Cuozzo A, Blasi A, Sculean A (2018). Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig, 22:597–615, Doi: 10.1007/s00784-017-2325-6. RamagliaL GuidaA Lorio-SicilianoV CuozzoA BlasiA SculeanA 2018 Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol Clin Oral Investig 22 597 615 10.1007/s00784-017-2325-6 Open DOISearch in Google Scholar

[60] Yamada SI, Kurita H, Kondo E, Suzuki S, Nishimaki F, Yoshimura N, et al (2019). Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review. Clin Oral Investig 23:3203–3211, doi: 10.1007/s00784-018-2743-0. YamadaSI KuritaH KondoE SuzukiS NishimakiF YoshimuraN 2019 Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review Clin Oral Investig 23 3203 3211 10.1007/s00784-018-2743-0 Open DOISearch in Google Scholar

[61] Nonnenmühlen N, Burnic A, Bartella A, Lethaus B, Gerhards F, Ristow O, et al (2019). Comparison of mucosal and mucoperiosteal wound cover for the treatment of medication-related osteonecrosis of the jaw lesions: a retrospective cohort study. Clin Oral Investig 23:351–359, doi: 10.1007/s00784-018-2443-9. NonnenmühlenN BurnicA BartellaA LethausB GerhardsF RistowO 2019 Comparison of mucosal and mucoperiosteal wound cover for the treatment of medication-related osteonecrosis of the jaw lesions: a retrospective cohort study Clin Oral Investig 23 351 359 10.1007/s00784-018-2443-9 Open DOISearch in Google Scholar

[62] Ristow O, Rückschloß T, Müller M, Berger M, Kargus S, Pautke C, et al (2019). Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg 47:491–499. RistowO RückschloßT MüllerM BergerM KargusS PautkeC 2019 Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study J Craniomaxillofac Surg 47 491 499 Search in Google Scholar

[63] Jung SY, Suh HS, Park JW, Kwon JW (2019). Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw. Oral Dis 25:471–480. JungSY SuhHS ParkJW KwonJW 2019 Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw Oral Dis 25 471 480 Search in Google Scholar

[64] Katsarelis H, Shah NP, Dhariwal DK, Pazianas M (2015). Infection and medication-related osteonecrosis of the jaw. J Dental Res 94:534–539, doi: 10.1177/0022034515572021. KatsarelisH ShahNP DhariwalDK PazianasM 2015 Infection and medication-related osteonecrosis of the jaw J Dental Res 94 534 539 10.1177/0022034515572021 Open DOISearch in Google Scholar

[65] Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D (2017). Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo 69:9–15, doi. 10.4081/reumatismo.207.983.. FassioA BertoldoF IdolazziL ViapianaO RossiniM GattiD 2017 Drug-induced osteonecrosis of the jaw: the state of the art Reumatismo 69 9 15 10.4081/reumatismo.207.983 Open DOISearch in Google Scholar

[66] Chang J, Hakan AE, McCauley LK (2018). Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep 16:584–595, doi.org/.10.1007/s11914-018-0474-4. ChangJ HakanAE McCauleyLK 2018 Current understanding of the pathophysiology of osteonecrosis of the jaw Curr Osteoporos Rep 16 584 595 doi.org/.10.1007/s11914-018-0474-4. Search in Google Scholar